A Long-term Follow-up Study of Efficacy and Immunogenicity of GEN-003 in Subjects With Genital Herpes Simplex Virus Type 2 (HSV-2) Infection

Trial Profile

A Long-term Follow-up Study of Efficacy and Immunogenicity of GEN-003 in Subjects With Genital Herpes Simplex Virus Type 2 (HSV-2) Infection

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 08 Oct 2017

At a glance

  • Drugs GEN 003 (Primary)
  • Indications Herpes simplex virus type 2 infections
  • Focus Therapeutic Use
  • Sponsors Genocea Biosciences
  • Most Recent Events

    • 08 Oct 2017 Primary endpoint (Long-term effect of GEN-003 on anogenital Herpes simplex virus type 2 (HSV-2) shedding) has been met as per the results presented at the IDWeek 2017.
    • 08 Oct 2017 Results presented at the IDWeek 2017
    • 19 Dec 2016 Planned End Date changed from 1 Nov 2018 to 1 Dec 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top